期刊文献+

肿瘤基因工程纳米疫苗的药效学研究 被引量:1

Pharmacodynamic study on nanoemulsion-encapsulated tumor specific antigen protein vaccine.
暂未订购
导出
摘要 目的观察肿瘤基因工程纳米疫苗对荷B16-MAGE-1肿瘤小鼠的疗效,并确定肿瘤抑制率分别为30%和50%的有效剂量和半数有效量(ED50)。方法超声乳化法制备包裹基因工程复合抗原(融合蛋白MAGE-1-HSP70与超抗原SEA按摩尔比1001混合)的纳米乳剂,皮下注入荷B16-MAGE-1肿瘤C57BL/6小鼠体内,设低、中、高(0.32mg,1mg和3.16mg/kg)3个剂量,并设阴性(生理盐水)、阳性(环磷酰胺)对照组。结果中剂量和高剂量的抑瘤率均大于30%,且和阴性对照组有显著性差异,三组剂量的对数值和肿瘤抑制率的线性关系为Y=39.795+lgX64.014(P<0.05),由此得到有效量和半数有效量分别为0.6952mg/kg和1.4607mg/kg。结论该肿瘤基因工程纳米疫苗NE(MAGE-1/HSP70/SEA)能有效地抑制肿瘤生长,是一种很有希望的新型抗肿瘤疫苗。 Objective To study the phannacodynamic effect of nanoemulsion - encapsulated tumor specific antigen protein vaccine on mice bearing B16 - MAGE - 1 tumor cells and to determine the effective dose and median effective dose corresponding to the 30% and 50% tumor suppressive rate. Methods Nanoemulsion - encapsulated complex protein vaccine (MAGE1/HSP70 fusion protein and superantigen SEA) was prepared using magnetic uhrasound methods. C57BL/6 mice were given nanovaccine via subcutaneous ( s. c. ) injections. The injection doses were 0.32mg, 1 mg and 3.16 mg/kg, respectively. While normal saline and cyclophosphamide were the negative and pesitire controls. Results Compared with the negative control,the median dose and high dose remarkably suppressed the growth of tumor,and both tumor suppressive rates were more than 30%. Linear function Y = 39.795 + 1gX 64.014( P 〈 0.05 ) showed the relationship between logarithm and the suppressive rate of the three doses. The effective dose and median effective dose were 0.6952mg/kg and 1. 4607mg/kg respectively according to the linear function. Conclusion The nanoemulsion can effectively inhibit the growth of B16 - MAGE - 1 tumor. We hope it can be used as new kind of vaccine against tumor.
出处 《现代肿瘤医学》 CAS 2006年第4期385-387,共3页 Journal of Modern Oncology
基金 国家自然科学基金资助项目(编号:30271464)
关键词 纳米乳剂 MAGE-1 HSP70 药效学 肿瘤疫苗 nanoemulsion MAGE- 1 HSP70 pharmacodynamics tumor vaccine
  • 相关文献

参考文献2

二级参考文献7

共引文献25

同被引文献5

  • 1Ye J, Chen GS, Song PIP, et al. Heat shock protein 70/MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo. Cancer Immunol Immunother, 2004, 53 (9) : 825
  • 2Ge W, Sui YF, Wu DC, et al. MAGE-1/Heat shock protein 70/ MAGE-3 fusion protein vaccine in nanoemulsion enhances cellular and humoral immune responses to MAGE-1 or MAGE-3 in vivo. Cancer Immunol Immunother, 2006, 55(7) : 841
  • 3Florence AT. Issues in oral nanoparticle drug carrier uptake and tar geting. J Drug Target, 2004, 12(2):65
  • 4Ogawa Y, Okada H, Yamamoto M, et al. In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly (lactic/ glycolic) acids and in vivo degradation of these polymers. Chem Pharm Bull, 1988, 36(7):2576
  • 5Damge C, Hillaire-Buys D, Puech R, et al. Effects of orally adminis tered insulin nanocapsules in normal and diabetic dogs. Diabetes Nutr Metab, 1995, 8(1):3

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部